Exclusive Summary

• Originator patents have fully expired globally, eliminating IP barriers and allowing overseas distributors to achieve rapid, risk-free registration and market launch.
• With over 254 million chronic hepatitis B patients worldwide, there is massive volume potential for cost-effective antivirals in emerging markets like Southeast Asia, Africa, and LATAM.
• While serving as a second-line therapy in updated guidelines, it holds confirmed clinical value for lamivudine-resistant patients and acts as a key combination option in resource-limited regions.
• Leveraging China's mature pharmaceutical supply chain, the product offers significant cost advantages and ready-to-file registration dossiers, yielding substantial profit margins for overseas partners.